Burning Rock Biotech Limited's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Burning Rock Biotech Limited's ROI in the fourth quarter of 2025?
Burning Rock Biotech Limited recorded a cumulative net loss of $-8 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -9.97%.

Within the Healthcare sector 311 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 3419, from total ROI ranking in the third quarter of 2025 at 3913.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Investment Change TTM	-2.52 %	-9.63 %	-15.6 %	-20.75 %	-25.24 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	82	78	78	78	83
Return On Investment (TTM)	-9.97 %	-59.67 %	-59.21 %	-58.75 %	-58.3 %
BNR's Overall Ranking	# 3419	# 3913	#	#	#
Seq. Investment Change TTM	-0.22 %	-0.78 %	-0.77 %	-0.77 %	-7.5 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-8	-47	-47	-47	-47

BNR Company Profile >> Back to BNR Roi Comparisons >> See Annual BNR Return On Investment

Return On Investment BNR's Ranking
Within:	No.
Industry	# 21
Sector	# 312
Overall	# 3419

Return On Investment Statistics
High	Average	Low
-9.97 %	-49.41 %	-84.57 %
(Dec 31 2025)		(Dec 31 2023)

News about Burning Rock Biotech Limited Return on Investment ROI

Amidst Financial Turmoil, Burning Rock and Bayer Forge Ahead with First NGS-Based Lung Cancer Diagnostic Approved by NMPA,

October 11, 2024

NMPA Approval of First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer Comes Amidst Financial Turbulence for Burning Rock BiotechIn a landmark achievement for the intersection of healthcare and technological innovation, the National Medical Products Administration (NMPA) in China has granted marketing approval for the first co-developed next-generation sequencing (NGS)-based companion diagnostic for lung cancer. This development marks a significant advancement in the field of oncology, especially given the rising tide of lung cancer cases worldwide. The partnership responsible for this innovation is a collaboration between Bayer, a leading pharmaceutical giant, and Burning Rock Biotech Limited, a company specializing in precision oncology. Bayer and Burning Rock: A Collaborative Effort Towards Precision MedicineBayer is a well-respected name in the pharmaceutical landscape, renowned for its commitment to advancing healthcare solutions across various medical disciplines. This collaboration with Burning Rock signifies Bayer s deepened focus on precision medicine, a strategy that promotes personalized therapies tailored to individual patient profiles. Burning Rock, on the other hand, has made substantial strides in the domain of molecular diagnostics, particularly through its AI-empowered NGS-DX Panel, which facilitates comprehensive genomic profiling. This innovative tool helps identify potential therapeutic targets based on the unique genetic makeup of a patient s cancer, enabling clinicians to make informed decisions regarding treatment options.

Financial Statements
Burning Rock Biotech Limited's IV. Quarter Investments	$ 82 Millions	BNR's Balance sheet
Burning Rock Biotech Limited's IV. Quarter Income	$ -8 Millions	Quarterly BNR's Income Statement
BNR's Income by Division		See BNR's Income by Division

BNR Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	80	83	109	171	296
Y / Y Investment Growth	-3.73 %	-24.18 %	-35.93 %	-42.38 %	-20.25 %
Net Income in Millions	-8	-47	-92	-141	-125
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-9.93 %	-57.33 %	-84.27 %	-82.58 %	-42.24 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Laboratories Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BNR's Roi Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BNR's Competitors
Subscribers only: Roi for Burning Rock Biotech Limited's Suppliers
Subscribers only: Return On Investment for BNR's Customers

Other Ratios
BNR's Roa	BNR's Inventory Turnover Ratio	BNR's Growth Rates	BNR's Dividend Statistics
	BNR's Profitability Ratios	BNR's Asset Turnover Ratio	BNR's Dividend Growth
BNR's Roe	BNR's Valuation Ratios	BNR's Financial Strength Ratios	BNR's Dividend Payout Ratio

Companies with similar Return On Investment at Dec 31 2025, within Healthcare Sector

ROI

Date modified: 2026-09-08T15:11:40+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.